Stayble Therapeutics AB (publ) has received approval to initiate a clinical phase Ib study with STA363 in patients suffering from chronic disc herniation. In parallel with the disc herniation project, the company is working on completing the phase IIb study in degenerative disc disease, while preparing for future partnerships. With two indications in the portfolio, the company's attractiveness and bargaining power in partnering discussions increase.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2435 SEK | +2.53% | -8.11% | -19.64% |
1st Jan change | Capi. | |
---|---|---|
-19.64% | 696K | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.49% | 21.25B | |
-5.61% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+37.57% | 12.54B | |
-26.24% | 8.09B |
- Stock Market
- Equities
- STABL Stock
- News Stayble Therapeutics AB
- Stayble Therapeutics AB Adds Disc Herniation to the Pipeline - Study Approved